Advertisement

Topics

Merck & Co., Samsung Bioepis terminate deal to develop Lantus biosimilar https://www.firstwordpharma.com/node/1597145?tsid=28®ion_id=6 …

17:55 EDT 12 Oct 2018 | FirstWord Pharma

Merck & Co., Samsung Bioepis terminate deal to develop Lantus biosimilar https://www.firstwordpharma.com/node/1597145?tsid=28&region_id=6 …

Original Article: Merck & Co., Samsung Bioepis terminate deal to develop Lantus biosimilar https://www.firstwordpharma.com/node/1597145?tsid=28®ion_id=6 …

NEXT ARTICLE

More From BioPortfolio on "Merck & Co., Samsung Bioepis terminate deal to develop Lantus biosimilar https://www.firstwordpharma.com/node/1597145?tsid=28®ion_id=6 …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...